SUNPHARMA

's Strategic Focus on Specialty Drugs Amid US Regulatory Uncertainty 💊

expects a limited impact from the new US "most favored nation" drug pricing directive. This is due to its focus on specialty products, which have low exposure to Medicaid, the US government's health insurance program for low-income individuals. Shifting Revenue Mix: The US is a major market, contributing 31% to Sun Pharma's FY25 consolidated revenue. However, the company's growth is increasingly driven by its specialty business, which includes dermatology, ophthalmology, and oncodermatology. This segment's revenue grew at a 26% CAGR between FY21 and FY25, and it now makes up 20% of total revenue, up from 11% in FY21. New Product Launches: Sun Pharma is launching new products to maintain this growth. Its recent launch of Leqselvi for severe alopecia areata has gained strong traction. The company also plans to introduce Unloxcyt for a type of skin cancer by Q4FY26. In India, it is set to be an early mover in the anti-obesity drug market with a generic version of Semaglutide. Regulatory and Financial Headwinds: Despite its strategic focus, Sun Pharma faces challenges. The company's overall earnings growth is expected to slow in FY26 due to an increase in its effective tax rate from 20% to 25%. Additionally, the company is grappling with a potential 50% US tariff on Indian imports, although it expects generics to remain exempt. Regulatory issues persist, with its Halol plant failing to meet regulatory requirements in a recent inspection. These uncertainties have contributed to a more than 13% decline in Sun Pharma's stock in 2025, a steeper drop than the Nifty Pharma index.